Defunct Company
Total Trials
7
As Lead Sponsor
5
As Collaborator
2
Total Enrollment
867
NCT00003991
Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
Phase: Phase 3
Role: Lead Sponsor
Start: Jul 31, 1998
Completion: Aug 31, 2011
NCT00039234
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
Start: Sep 30, 2002
Completion: Not specified
NCT01354691
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
Phase: Phase 2
Start: Feb 28, 2011
Completion: Mar 31, 2013
NCT01429623
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
Start: Feb 29, 2012
Completion: Sep 30, 2016
NCT01933529
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
Role: Collaborator
Start: Oct 31, 2013
Completion: Dec 31, 2015
NCT02039687
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
Start: Jan 31, 2014
Completion: Feb 28, 2015
NCT06626971
The Use of ARA290 for the Treatment of Diabetic Macular Oedema
Start: Apr 30, 2016
Completion: Aug 31, 2017